uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Sequential Intravesical Chemoimmunotherapy with Mitomycin C and Bacillus Calmette-Guerin and with Bacillus Calmette-Guerin Alone in Patients with Carcinoma in Situ of the Urinary Bladder: Results of an EORTC Genito-Urinary Group Randomized Phase 2 Trial (30993)
Show others and affiliations
2011 (English)In: European Urology, ISSN 0302-2838, E-ISSN 1873-7560, Vol. 59, no 3, 438-446 p.Article in journal (Refereed) Published
Abstract [en]

Background: Bacillus Calmette-Guerin (BCG) is the intravesical treatment of choice for carcinoma in situ (CIS). Objective: Our aim was to assess if sequential mitomycin C (MMC) plus BCG after transurethral resection (TUR) is worthy of further study in non-muscle-invasive bladder cancer patients with CIS. Design, setting, and participants: In a noncomparative phase 2 study, 96 patients with primary/secondary/concurrent CIS of the urinary bladder were randomized to sequential MMC plus BCG or to BCG alone after TUR. Intervention: Patients received six weekly instillations of MMC followed by six weekly instillations of BCG or six weekly instillations of BCG, 3 wk rest, and three further weekly instillations of BCG. Complete responders received three weekly maintenance instillations at 6, 12, 18, 24, 30, and 36 mo in accordance with the initial randomization. Measurements: End points were complete response (CR) rate at the first control cystoscopy 16-18 wk after start of treatment, disease-free interval, overall survival, and side effects. Results and limitations: Ninety-six patients were randomized, 48 to each treatment group. Ten patients were ineligible, and three did not start treatment. In all random-ized patients, CR rates on MMC plus BCG and BCG alone were 70.8% and 66.7%, respectively. In 83 eligible patients who started treatment, CR rates were 75.6% and 73.8%, respectively. Based on a median follow-up of 4.7 yr, 25 patients (52.1%) on MMC plus BCG and 22 patients (45.8%) on BCG alone were disease free. Twelve patients stopped treatment due to toxicity: three during induction (two MMC plus BCG, one BCG) and nine during maintenance (three MMC plus BCG, six BCG). Conclusions: In the treatment of patients with CIS, sequential chemoimmunotherapy with MMC plus BCG had acceptable toxicity. CR and disease-free rates were similar to those on BCG alone and to previous publications on sequential chemoimmunotherapy.

Place, publisher, year, edition, pages
2011. Vol. 59, no 3, 438-446 p.
Keyword [en]
Bacillus Calmette-Guerin, Carcinoma in situ, Intravesical therapy, Mitomycin C, Non-muscle-invasive bladder cancer, Randomized clinical trial, Urinary bladder
National Category
Medical and Health Sciences
URN: urn:nbn:se:uu:diva-148966DOI: 10.1016/j.eururo.2010.11.038ISI: 000286658600030OAI: oai:DiVA.org:uu-148966DiVA: diva2:403531
Available from: 2011-03-14 Created: 2011-03-14 Last updated: 2012-05-14Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full text

Search in DiVA

By author/editor
Busch, Christer
By organisation
Molecular and Morphological Pathology
In the same journal
European Urology
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 137 hits
ReferencesLink to record
Permanent link

Direct link